Amphenol Corporation (APH) vs Cellebrite DI Ltd. (CLBT)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| APH | CLBT | |
|---|---|---|
| Sector | Technology | Technology |
| Industry | Electronic Components | Software - Infrastructure |
| Size band | LARGE | MID |
| Listing | NYSE | Nasdaq GS |
| Country | United States | Israel |
| Theme | telecom-equipment | saas |
| Price and returns | ||
| Last close | $75.27 | $12.23 |
| Return · 1 week | −6.24% | +9.74% |
| Return · 1 month | −11.05% | +10.48% |
| Return · 3 months | −47.67% | −17.64% |
| Return · year to date | −46.02% | −31.45% |
| Return · 1 year | −44.40% | −33.89% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −57.84% | −38.79% |
| 52-week high | $178.52 | $19.98 |
| 52-week low | $71.44 | $9.58 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $185.61B | $3.07B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $768.17M | $30.96M |
| Employees | 170,000 | 1,285 |
| Valuation | ||
| Price to earnings · trailing | 37.05× | 52.61× |
| Price to earnings · forward | 22.22× | 18.52× |
| Price to sales | 6.30× | 5.91× |
| Price to book | 11.79× | 5.64× |
| Enterprise value to EBITDA | 20.74× | 33.35× |
| Enterprise value to revenue | 6.76× | 5.09× |
| PEG ratio | 0.85 | — |
| Earnings per share · trailing | 2.00 | 0.23 |
| Profitability | ||
| Gross margin | 38.50% | 82.96% |
| Operating margin | 29.78% | 5.30% |
| Profit margin | 17.73% | 11.33% |
| Return on equity | 38.12% | 12.42% |
| Return on assets | 14.47% | 3.92% |
| Growth | ||
| Revenue growth | +55.00% | +15.80% |
| Earnings growth | +59.30% | −67.90% |
| Balance sheet and payout | ||
| Debt / equity (%) | 120.42 | 4.32 |
| Current ratio | 1.89 | 1.62 |
| Dividend yield | 0.67% | 0.00% |
| Payout ratio | 22.88% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 31.93 | 61.35 |
| ADX · 14 | 41.77 | 19.14 |
| 50-day average | $89.36 | $11.41 |
| 200-day average | $132.19 | $13.52 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 4.02% | 3.17% |
The full APH analysis
Everything this table leaves out for Amphenol Corporation: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the APH argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full APH analysisThe full CLBT analysis
Everything this table leaves out for Cellebrite DI Ltd.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the CLBT argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full CLBT analysis